Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Dose intensification of chemotherapy and the combination of a third cytotoxic agent with standard cytarabine and anthracycline-based induction chemotherapy have led to improved outcomes in select groups of patients with acute myeloid leukemia (AML). However, despite some progress in this area, it appears that we might be reaching the limit of cytotoxic chemotherapy for the treatment of AML, especially in older patients and in those with poor-risk features whose disease tends to be relatively chemoresistant.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Nicholas J. Short, Farhad Ravandi Tags: SOHO Supplement 2016 Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma